Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gefapixant: First Approval.

Drugs·2022
Same author

Daridorexant: First Approval.

Drugs·2022
Same author

Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.

Targeted oncology·2022
Same author

Envafolimab: First Approval.

Drugs·2022
Same author

Tisotumab Vedotin: First Approval.

Drugs·2021
Same author

Mobocertinib: First Approval.

Drugs·2021
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Feb 28, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K

Brigatinib: First Global Approval.

Anthony Markham1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|June 10, 2017
PubMed
Summary
This summary is machine-generated.

Brigatinib is a new ALK inhibitor approved for ALK-positive metastatic non-small cell lung cancer (NSCLC) patients who progressed on crizotinib. It offers a crucial option for managing treatment resistance.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Related Experiment Videos

Last Updated: Feb 28, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) presents a therapeutic challenge, particularly with resistance to existing treatments like crizotinib.
  • Brigatinib is a second-generation ALK inhibitor developed to overcome resistance mechanisms.
  • Crizotinib resistance necessitates the development of novel therapeutic agents targeting ALK mutations.

Purpose of the Study:

  • To summarize the developmental milestones of brigatinib.
  • To highlight brigatinib's approval for ALK-positive metastatic NSCLC patients with prior crizotinib treatment.
  • To provide an overview of brigatinib's role in managing treatment-resistant ALK-positive NSCLC.

Main Methods:

  • Review of preclinical and clinical development data for brigatinib.
  • Analysis of regulatory submission and approval processes.
  • Summary of brigatinib's mechanism of action against ALK mutants.

Main Results:

  • Brigatinib received accelerated approval in the USA in April 2017.
  • The approval targets patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
  • Brigatinib demonstrates activity against treatment-resistant ALK mutants.

Conclusions:

  • Brigatinib represents a significant advancement in the treatment of ALK-positive metastatic NSCLC.
  • The drug addresses the unmet need for effective therapies in patients resistant to crizotinib.
  • This approval marks a key milestone in the clinical application of targeted ALK inhibition.